Please assess the completion status of the following clinical trial:

Trial Title: Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Aged between 2 months and 2 months plus 2 weeks (Arms A-F) or aged between 18 months and 18 months plus 2 weeks (Arm G)~* No significant maternal or perinatal history~* Born at or after 36 weeks gestation~* Written and signed informed consent from parent/legal guardian~* Lives within approximately 30 minutes of the commune health centre~* Family anticipates living in the study area for the next 22 months (Arms A-F) or 6 months (Arm G)~* Has received three doses of either Infanrix-hexa or Quinvaxem in infancy (Arm G)~Exclusion Criteria:~* Known allergy to any component of the vaccine~* Allergic reaction or anaphylactic reaction to any previous vaccine~* Known immunodeficiency disorder~* Known HIV-infected mother~* Known thrombocytopenia or coagulation disorder~* On immunosuppressive medication~* Administration or planned administration of any immunoglobulin or blood product since birth~* Severe birth defect requiring ongoing medical care~* Chronic or progressive disease~* Seizure disorder~* History of invasive pneumococcal, meningococcal or Haemophilus influenzae type b diseases, or tetanus, measles, pertussis or diphtheria infections~* Receipt of any 2 month vaccines through the EPI program (Arms A-F) or receipt of PCV (Arm G)~* Family plans on giving the infant Quinvaxem or oral polio vaccine (Arms A-F)

- Gender: ALL
- Minimum Age: 60 Days
- Maximum Age: 74 Days
- Healthy Volunteers: t

Study Arms:
- A: 3+1 PCV10 (Type: ACTIVE_COMPARATOR): PCV10 administered at 2, 3, 4 and 9 months of age
- B: 3+0 PCV10 (Type: EXPERIMENTAL): PCV10 administered at 2, 3 and 4 months of age
- C: 2+1 PCV10 (Type: EXPERIMENTAL): PCV10 administered at 2, 4 and 9 months of age
- D: 1+1 PCV10 (Type: EXPERIMENTAL): PCV10 administered at 2 and 6 months of age
- E: 2+1 PCV13 (Type: EXPERIMENTAL): PCV13 administered at 2, 4 and 9 months of age
- F: control (Type: NO_INTERVENTION): No infant PCV vaccination. PCV10 administered at 18 and 24 months of age
- G: control (Type: NO_INTERVENTION): Recruited at 18 months of age (non-randomised). PCV10 administered at 24 months of age

Based on this trial design, predict the completion outcome and termination type (if applicable).